Presently, alternative approaches using DLL3 for T cell-redirecting therapies are in clinical trials [44], and the experience gained from these therapies will help determine whether DLL3 or other Notch pathway inhibitors are promising targets in SCLC, considering the pro-tumorigenic role of the Notch pathway in the non-neuroendocrine subgroup. The gene discussed is DLL3; the disease is small cell lung carcinoma.